| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary targets of FMOC-AM are not biological targets but rather chemical reaction partners in peptide synthesis. The compound serves as a linker for solid-phase peptide synthesis, providing a handle for the attachment of amino acids to a solid support. The Fmoc (9-fluorenylmethoxycarbonyl) group serves as a temporary protecting group for the amino terminus, allowing for selective deprotection and chain elongation.
|
|---|---|
| ln Vitro |
In vitro activity for FMOC-AM refers to its chemical reactivity in peptide synthesis. The compound is used as a solid-phase carrier basis for peptide chain synthesis. The Fmoc group can be selectively removed under mild basic conditions, allowing for the sequential addition of amino acids. The compound's stability and reactivity make it suitable for automated peptide synthesis.
|
| ln Vivo |
In vivo activity data are not applicable for FMOC-AM, as it is a chemical reagent used in peptide synthesis rather than a pharmacologically active compound. The compound is not intended for biological or therapeutic applications. Its use is limited to organic synthesis and peptide chemistry.
|
| Enzyme Assay |
Non-cellular assays for FMOC-AM typically involve characterization of its chemical properties and purity. Standard analytical techniques include NMR spectroscopy, HPLC, and mass spectrometry to confirm identity and purity. The compound's reactivity in peptide coupling reactions is assessed by monitoring the efficiency of peptide chain elongation. Solubility testing is performed in common organic solvents for synthetic applications.
|
| Cell Assay |
Cellular assays are not applicable for FMOC-AM, as it is a chemical reagent not intended for cell-based studies. The compound is used in peptide synthesis, but it is not studied for biological activity in cell culture systems. Its use is limited to chemical reactions outside of living systems.
|
| Animal Protocol |
In vivo animal experiments are not conducted for FMOC-AM, as it is a chemical reagent rather than a therapeutic or pharmacological compound. The compound is not administered to animals for any research purpose. Its applications are strictly limited to synthetic chemistry as a linker for peptide synthesis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable for FMOC-AM, as it is a chemical reagent and not a pharmaceutical compound. The compound has a molecular weight of 539.58 g/mol. It should be stored at room temperature for up to 3 years or in solvent at -80°C for 2 years. Solubility information and stability data are available from chemical suppliers for synthetic chemistry applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for FMOC-AM are limited, as it is a chemical reagent not intended for human use. Standard laboratory safety precautions should be followed when handling the compound. It may be irritating to skin, eyes, and respiratory tract. Appropriate personal protective equipment should be worn when handling the compound.
|
| References |
[1]. Eyleen Araya, et al. Gold Nanoparticles and Microwave Irradiation Inhibit Beta-Amyloid Amyloidogenesis. Nanoscale Res Lett. 2008; 3(11): 435-443.
|
| Additional Infomation |
Other information includes FMOC-AM's role as a derivative of aminomethyl resin and a protein cross-linking agent. It is used in solid-phase peptide synthesis. The compound is also known as Fmoc-Knorr linker, Fmoc-Rink linker, and Rink amide linker. It provides a solid-phase carrier basis for peptide chain synthesis. The Fmoc group allows for selective deprotection under mild basic conditions, making it suitable for automated peptide synthesis. The compound is available as a research reagent with ≥98% purity.
|
| Molecular Formula |
C32H29NO7
|
|---|---|
| Molecular Weight |
539.58
|
| Exact Mass |
539.194
|
| CAS # |
126828-35-1
|
| PubChem CID |
2761459
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
747.1±60.0 °C at 760 mmHg
|
| Melting Point |
180ºC (DEC.)
|
| Flash Point |
405.6±32.9 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.639
|
| LogP |
4.93
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
40
|
| Complexity |
808
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(OC)=C(C(NC(OCC2C3=CC=CC=C3C4=CC=CC=C42)=O)C5=CC=C(OCC(O)=O)C=C5)C=C1
|
| InChi Key |
UPMGJEMWPQOACJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H29NO7/c1-37-22-15-16-27(29(17-22)38-2)31(20-11-13-21(14-12-20)39-19-30(34)35)33-32(36)40-18-28-25-9-5-3-7-23(25)24-8-4-6-10-26(24)28/h3-17,28,31H,18-19H2,1-2H3,(H,33,36)(H,34,35)
|
| Chemical Name |
2-[4-[(2,4-dimethoxyphenyl)-(9H-fluoren-9-ylmethoxycarbonylamino)methyl]phenoxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8533 mL | 9.2665 mL | 18.5329 mL | |
| 5 mM | 0.3707 mL | 1.8533 mL | 3.7066 mL | |
| 10 mM | 0.1853 mL | 0.9266 mL | 1.8533 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
